Evidence map›Paper›PMID 42467726›Full record

ArticlePloS one2026

Difference in excess mortality during the COVID-19 pandemic depending on marital status in Japan.

Tasuku Okui

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Tasuku OkuiMedical Information Center, Kyushu University Hospital, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-5098-8502

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differences in excess mortality during the coronavirus disease 2019 pandemic across marital statuses in Japan were investigated using data from across the country. Mortality data from the Vital Statistics records spanning 2010-2023 were utilized. Age-standardized mortality rates were computed by sex, marital status, year, and cause of death, and expected post-pandemic rates were estimated using pre-pandemic values with a quasi-Poisson regression model. Furthermore, the age-standardized percentage of the excess number of deaths relative to the expected number of deaths (hereafter, P-score) after the pandemic started was calculated by sex, marital status, and cause of death, using the expected and observed number of deaths. A declining trend in all-cause mortality rate was observed across all groups before the pandemic, regardless of sex and marital status, while mortality rates increased across all groups after the pandemic began. The largest decrease in all-cause mortality rate was observed among never-married persons before the pandemic in both men and women, while the smallest increase after the pandemic was observed among married persons. The highest age-standardized P-score for all-cause mortality was observed among never-married men and women, while that for married persons was the lowest among men. For women, the age-standardizedP-scores were closer across groups, with confidence intervals overlapping among marital-status categories. In contrast, there was a significant difference in the age-standardized P-scores between never-married and married persons among women aged <65 years. In conclusion, the percentage of excess all-cause mortality was the highest among never-married persons during the pandemic period in Japan, particularly in men, and it is important to continue to monitor the trend in the future.

Indexed as

COVID-19Marital StatusAdultAgedCause of DeathFemaleHumansJapanMaleMiddle AgedMortalityPandemicsSARS-CoV-2

Identifiers

PMID42467726
PMCPMC13379106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.